Velcade review

Velcade is the first proteasome inhibitor tested on humans for therapeutic purposes. It is currently an approved treatment in the United States for cases of mantle cell lymphoma and relapsed multiple myeloma and is available in IV injections. Bortezmoib works by inihibiting the function of certain protein-producing enzymes found inside cancer cells. This limits their growth and may stop the spread of the tumor.

Velcade is often given to people who have multiple myeloma and mantle cell lymphoma when at least one other medication or treatment used previously seems to have no effect at all.

Velcade is available as an injection solution that is administered through a vein. It may be administered via a central line inserted into a vein beneath the skin near the collarbone, or via a PICC line inserted into a vein near the bend of the arm. The schedule of doses usually alternates 2 weeks when Velcade is administered 2 times a week followed by 10 days when the medication is not given. Each dose is given a 72-hour buffer period during this critical time where the medication is being administered. The schedule may go on for eight cycles. If the doctor decides to continue your treatment, he may have to administer smaller doses of the medication.

Before administering Velcade in the IV, check the solution for any visible particles or any discoloration. If either is found in the medication, do not attempt to administer the solution.

Minor side effects include weakness and anxiety, nausea and vomiting, stomach pain, diarrhea, body pains and difficulty sleeping or staying awake. Consult with your doctor if these symptoms persist.

Some side effects may need immediate medical attention. These include severe allergy symptoms such as persistent fevers, rashes, swelling, unusual color or presence of blood in stool, mental confusion, loss of coordination, irregular heartbeats, fainting and painful or burning sensations in the hands.

Inform your doctor if you are going to be undergoing surgery while on this medication, to prepare for any conflicting medication. Also, inform your doctor of your medical history with emphasis on any cases of heart disease, high cholesterol, herpes infection, blood pressure conditions or any liver o kidney disease. These conditions may hinder you from taking Velcade. List all current medication you are taking and give a copy to your doctor so that any conflicting medication can be anticipated and dealt with.

Velcade will cause somnolence, so be careful when performing dangerous or complicated tasks. Drink plenty of water to remain hydrated and avoid alcohol while taking Velcade. Ask your doctor if consuming grapefruit would be safe while taking this medication.

Get up to your feet or from bed slowly while taking Velcade, as you are more prone to fainting due to dehydration or blood pressure medicaments.

Velcade has the following structural formula:

Chemical structure of velcade

• Molecular formula of velcade is C19H25BN4O4
• Chemical IUPAC Name is [3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl)amino-butyl]boronic acid
• Molecular weight is 384.237 g/mol

Generic name: Bortezomib

  Your Velcade review